中国药业2011，Vol.20Issue(3)：41-42,2.
伊立替康临床应用的安全性研究
Safety Study on Clinical Application of Irinotecan
王伟兰 1朱曼 1郭代红 1刘皈阳1
作者信息
- 1. 中国人民解放军总医院药品保障中心,北京,100853
- 折叠
摘要
Abstract
Objective To retrospectively analyze the major adverse reactions and the relative risk factors of late- onset diarrhea for improving the application security of irinotecan. Methods With the help of hospital PASS system, the information of 60 cases using only irinotecan or combination chemotherapy from January to June 2009 in the oncology department of our hospital were collected and retrospectively analyzed on adverse reactions and safety. The Crosstabs method was adopted to study and analyze the relations between different kinds of patients' clinical and pathological parameters with adverse reactions. Results The incidence of bone marrow suppression was 75.00％,severe bone marrow suppression (above Ⅲ degrees) incidence was 10.00％; delayed diarrhea incidence was 40. 00％, severe diarrhea (above Ⅲ degrees) incidence was 10. 00％;acute cholinergic syndrome incidence was 40. 00％;the incidence of nausea and vomiting was 86.67％, the incidence of severe nausea and vomiting (above Ⅲ degrees) was 8.33％. The risk factor of tardive diarrhea was age. Conclusion The major adverse reactions of irinotecan are bone marrow suppression and gastrointestinal reactions. Delayed diarrhea caused by irinotecan is age-related. Using irinotecan in elderly patients, especially over the age of 70, intensive care should be strengthened, if necessary, dosage should be adjusted. Taking orally NaHCO3 or gentamycin may prevent intestinal toxicity of irinotecan.关键词
伊立替康/不良反应/迟发性腹泻/危险因素分类
医药卫生引用本文复制引用
王伟兰,朱曼,郭代红,刘皈阳..伊立替康临床应用的安全性研究[J].中国药业,2011,20(3):41-42,2.
